Loading patent…
AssigneesLes Laboratories Servier, Institut National de Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifiaue (CNRS)
InventorsJulie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
Estimating the term…
The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
A monoclonal antibody that specifically binds a human progastrin (hPG) polypeptide having an amino acid sequence of SEQ ID NO:20, but does not detectably bind to an amidated gastrin 17 consisting of SEQ ID NO:103, a glycine-extended gastrin 17 consisting of SEQ ID NO:104, or C-terminal Flanking Peptide (CTFP) consisting of SEQ ID NO:105, wherein said monoclonal antibody is a N-terminal anti-hPG monoclonal antibody that specifically binds a N-terminal region of hPG, wherein:
A monoclonal antibody that specifically binds a human progastrin (hPG) polypeptide having an amino acid sequence of SEQ ID NO:20, but does not detectably bind to an amidated gastrin 17 consisting of SEQ ID NO:103, a glycine-extended gastrin 17 consisting of SEQ ID NO:104, or C-terminal Flanking Peptide (CTFP) consisting of SEQ ID NO:105, wherein said monoclonal antibody is a N-terminal anti-hPG monoclonal antibody that specifically binds a N-terminal region of hPG, wherein:
A monoclonal antibody that specifically binds a human progastrin (hPG) polypeptide having an amino acid sequence of SEQ ID NO:20, but does not detectably bind to an amidated gastrin 17 consisting of SEQ ID NO:103, a glycine-extended gastrin 17 consisting of SEQ ID NO:104, or C-terminal Flanking Peptide (CTFP) consisting of SEQ ID NO:105, wherein said monoclonal antibody is a N-terminal anti-hPG monoclonal antibody that specifically binds a N-terminal region of hPG, wherein:
A monoclonal antibody that specifically binds a human progastrin polypeptide and comprises a VH chain comprising CDRs having the amino acid sequence of VH CDR 1.4 (SEQ ID NO:7), VH CDR 2.4 (SEQ ID NO:8), VH CDR 3.4 (SEQ ID NO:9) and VL CDRs comprising amino acid sequences of VL CDR 1.4 (SEQ ID NO:10), VL CDR 2.4 (SEQ ID NO:5), and VL CDR 3.4 (SEQ ID NO:11).
A cell line which recombinantly expresses an anti-human progastrin antibody comprising a VH of SEQ ID NO:14 and a VL of SEQ ID NO:15.
Dependencies are inferred from the claim text.